Postmastectomy radiotherapy in patients with T 1-2 N 1 breast cancer: a single center experience and a meta-analysis
Postmastectomy radiotherapy (PMRT) in patients with T N breast cancer is still controversial. This study was to evaluate the survival prognosis of T N patients with or without PMRT. From January 2006 to May 2017, 2606 female breast cancer patients underwent mastectomy in our medical center, among wh...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2023-09, Vol.149 (12), p.9979 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 9979 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 149 |
| creator | Luo, Meng Jin, Yao Xu, Chunjing Chen, Huihui Zhang, Kun Chen, Qiang Jin, Chencan Lu, Jinglu Wang, Jing Huang, Jia Deng, Hao Jin, Weili Zheng, Shu Chen, Yiding Zhou, Jiaojiao |
| description | Postmastectomy radiotherapy (PMRT) in patients with T
N
breast cancer is still controversial. This study was to evaluate the survival prognosis of T
N
patients with or without PMRT.
From January 2006 to May 2017, 2606 female breast cancer patients underwent mastectomy in our medical center, among whom 402 patients of T
N
stage with or without PMRT were finally analyzed. The median follow-up duration was 59.5 months. The primary endpoint was overall survival (OS). The secondary endpoint was disease-free survival (DFS).
In the study of our center, no statistically significant difference was observed between the T
N
PMRT and non-PMRT subgroups for the 5-year OS (94.4% vs 95.4%, p = 0.667) and DFS (90.1% vs. 91.1%, p = 0.798). By the date of the last follow-up, 8.96% (n = 36) of the patients experienced any recurrence. Univariate analysis revealed that PMRT was not a prognostic factor for either OS (p = 0.667) or DFS (p = 0.798) in T
N
patients. We then did a meta-analysis on the current treatment patterns, in which 2606 PMRT and 4281 non-PMRT T
N
breast cancer patients with mastectomy were included. The meta-analysis showed that PMRT didn't improve the OS of the patients (HR = 0.85, p = 0.11), but patients with PMRT had better DFS than those in the non-PMRT group (HR = 0.62, p |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_37256383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37256383</sourcerecordid><originalsourceid>FETCH-pubmed_primary_372563833</originalsourceid><addsrcrecordid>eNqFjsGKwjAURcOAjNXxF4b3A4WmmVqZ7aC4Ehfu5TV9jpEmDXlPtH9vF7p2dRfnHLgfKtM_psy1MdVUzZgvRaHrqi4_1dTUZbU0K5Mp2fcsHlnISu8HSNi6Xs6UMA7gAkQUR0EYbk7OcACdl7ADDU2iMQKLwVL6BQR24b8jsKNMCegeKY2hJcDQjtiTYI4Bu4Edf6nJCTumxXPn6nuzPvxt83htPLXHmJzHNBxfN81b4QGlCkik</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Postmastectomy radiotherapy in patients with T 1-2 N 1 breast cancer: a single center experience and a meta-analysis</title><source>SpringerLink Journals - AutoHoldings</source><creator>Luo, Meng ; Jin, Yao ; Xu, Chunjing ; Chen, Huihui ; Zhang, Kun ; Chen, Qiang ; Jin, Chencan ; Lu, Jinglu ; Wang, Jing ; Huang, Jia ; Deng, Hao ; Jin, Weili ; Zheng, Shu ; Chen, Yiding ; Zhou, Jiaojiao</creator><creatorcontrib>Luo, Meng ; Jin, Yao ; Xu, Chunjing ; Chen, Huihui ; Zhang, Kun ; Chen, Qiang ; Jin, Chencan ; Lu, Jinglu ; Wang, Jing ; Huang, Jia ; Deng, Hao ; Jin, Weili ; Zheng, Shu ; Chen, Yiding ; Zhou, Jiaojiao</creatorcontrib><description>Postmastectomy radiotherapy (PMRT) in patients with T
N
breast cancer is still controversial. This study was to evaluate the survival prognosis of T
N
patients with or without PMRT.
From January 2006 to May 2017, 2606 female breast cancer patients underwent mastectomy in our medical center, among whom 402 patients of T
N
stage with or without PMRT were finally analyzed. The median follow-up duration was 59.5 months. The primary endpoint was overall survival (OS). The secondary endpoint was disease-free survival (DFS).
In the study of our center, no statistically significant difference was observed between the T
N
PMRT and non-PMRT subgroups for the 5-year OS (94.4% vs 95.4%, p = 0.667) and DFS (90.1% vs. 91.1%, p = 0.798). By the date of the last follow-up, 8.96% (n = 36) of the patients experienced any recurrence. Univariate analysis revealed that PMRT was not a prognostic factor for either OS (p = 0.667) or DFS (p = 0.798) in T
N
patients. We then did a meta-analysis on the current treatment patterns, in which 2606 PMRT and 4281 non-PMRT T
N
breast cancer patients with mastectomy were included. The meta-analysis showed that PMRT didn't improve the OS of the patients (HR = 0.85, p = 0.11), but patients with PMRT had better DFS than those in the non-PMRT group (HR = 0.62, p < 0.001).
PMRT did not affect the survival of T
N
breast cancer patients who underwent mastectomy, suggesting that radiotherapy may be safely omitted for them.</description><identifier>EISSN: 1432-1335</identifier><identifier>PMID: 37256383</identifier><language>eng</language><publisher>Germany</publisher><ispartof>Journal of cancer research and clinical oncology, 2023-09, Vol.149 (12), p.9979</ispartof><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37256383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luo, Meng</creatorcontrib><creatorcontrib>Jin, Yao</creatorcontrib><creatorcontrib>Xu, Chunjing</creatorcontrib><creatorcontrib>Chen, Huihui</creatorcontrib><creatorcontrib>Zhang, Kun</creatorcontrib><creatorcontrib>Chen, Qiang</creatorcontrib><creatorcontrib>Jin, Chencan</creatorcontrib><creatorcontrib>Lu, Jinglu</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Huang, Jia</creatorcontrib><creatorcontrib>Deng, Hao</creatorcontrib><creatorcontrib>Jin, Weili</creatorcontrib><creatorcontrib>Zheng, Shu</creatorcontrib><creatorcontrib>Chen, Yiding</creatorcontrib><creatorcontrib>Zhou, Jiaojiao</creatorcontrib><title>Postmastectomy radiotherapy in patients with T 1-2 N 1 breast cancer: a single center experience and a meta-analysis</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>Postmastectomy radiotherapy (PMRT) in patients with T
N
breast cancer is still controversial. This study was to evaluate the survival prognosis of T
N
patients with or without PMRT.
From January 2006 to May 2017, 2606 female breast cancer patients underwent mastectomy in our medical center, among whom 402 patients of T
N
stage with or without PMRT were finally analyzed. The median follow-up duration was 59.5 months. The primary endpoint was overall survival (OS). The secondary endpoint was disease-free survival (DFS).
In the study of our center, no statistically significant difference was observed between the T
N
PMRT and non-PMRT subgroups for the 5-year OS (94.4% vs 95.4%, p = 0.667) and DFS (90.1% vs. 91.1%, p = 0.798). By the date of the last follow-up, 8.96% (n = 36) of the patients experienced any recurrence. Univariate analysis revealed that PMRT was not a prognostic factor for either OS (p = 0.667) or DFS (p = 0.798) in T
N
patients. We then did a meta-analysis on the current treatment patterns, in which 2606 PMRT and 4281 non-PMRT T
N
breast cancer patients with mastectomy were included. The meta-analysis showed that PMRT didn't improve the OS of the patients (HR = 0.85, p = 0.11), but patients with PMRT had better DFS than those in the non-PMRT group (HR = 0.62, p < 0.001).
PMRT did not affect the survival of T
N
breast cancer patients who underwent mastectomy, suggesting that radiotherapy may be safely omitted for them.</description><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFjsGKwjAURcOAjNXxF4b3A4WmmVqZ7aC4Ehfu5TV9jpEmDXlPtH9vF7p2dRfnHLgfKtM_psy1MdVUzZgvRaHrqi4_1dTUZbU0K5Mp2fcsHlnISu8HSNi6Xs6UMA7gAkQUR0EYbk7OcACdl7ADDU2iMQKLwVL6BQR24b8jsKNMCegeKY2hJcDQjtiTYI4Bu4Edf6nJCTumxXPn6nuzPvxt83htPLXHmJzHNBxfN81b4QGlCkik</recordid><startdate>202309</startdate><enddate>202309</enddate><creator>Luo, Meng</creator><creator>Jin, Yao</creator><creator>Xu, Chunjing</creator><creator>Chen, Huihui</creator><creator>Zhang, Kun</creator><creator>Chen, Qiang</creator><creator>Jin, Chencan</creator><creator>Lu, Jinglu</creator><creator>Wang, Jing</creator><creator>Huang, Jia</creator><creator>Deng, Hao</creator><creator>Jin, Weili</creator><creator>Zheng, Shu</creator><creator>Chen, Yiding</creator><creator>Zhou, Jiaojiao</creator><scope>NPM</scope></search><sort><creationdate>202309</creationdate><title>Postmastectomy radiotherapy in patients with T 1-2 N 1 breast cancer: a single center experience and a meta-analysis</title><author>Luo, Meng ; Jin, Yao ; Xu, Chunjing ; Chen, Huihui ; Zhang, Kun ; Chen, Qiang ; Jin, Chencan ; Lu, Jinglu ; Wang, Jing ; Huang, Jia ; Deng, Hao ; Jin, Weili ; Zheng, Shu ; Chen, Yiding ; Zhou, Jiaojiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_372563833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luo, Meng</creatorcontrib><creatorcontrib>Jin, Yao</creatorcontrib><creatorcontrib>Xu, Chunjing</creatorcontrib><creatorcontrib>Chen, Huihui</creatorcontrib><creatorcontrib>Zhang, Kun</creatorcontrib><creatorcontrib>Chen, Qiang</creatorcontrib><creatorcontrib>Jin, Chencan</creatorcontrib><creatorcontrib>Lu, Jinglu</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Huang, Jia</creatorcontrib><creatorcontrib>Deng, Hao</creatorcontrib><creatorcontrib>Jin, Weili</creatorcontrib><creatorcontrib>Zheng, Shu</creatorcontrib><creatorcontrib>Chen, Yiding</creatorcontrib><creatorcontrib>Zhou, Jiaojiao</creatorcontrib><collection>PubMed</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luo, Meng</au><au>Jin, Yao</au><au>Xu, Chunjing</au><au>Chen, Huihui</au><au>Zhang, Kun</au><au>Chen, Qiang</au><au>Jin, Chencan</au><au>Lu, Jinglu</au><au>Wang, Jing</au><au>Huang, Jia</au><au>Deng, Hao</au><au>Jin, Weili</au><au>Zheng, Shu</au><au>Chen, Yiding</au><au>Zhou, Jiaojiao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postmastectomy radiotherapy in patients with T 1-2 N 1 breast cancer: a single center experience and a meta-analysis</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2023-09</date><risdate>2023</risdate><volume>149</volume><issue>12</issue><spage>9979</spage><pages>9979-</pages><eissn>1432-1335</eissn><abstract>Postmastectomy radiotherapy (PMRT) in patients with T
N
breast cancer is still controversial. This study was to evaluate the survival prognosis of T
N
patients with or without PMRT.
From January 2006 to May 2017, 2606 female breast cancer patients underwent mastectomy in our medical center, among whom 402 patients of T
N
stage with or without PMRT were finally analyzed. The median follow-up duration was 59.5 months. The primary endpoint was overall survival (OS). The secondary endpoint was disease-free survival (DFS).
In the study of our center, no statistically significant difference was observed between the T
N
PMRT and non-PMRT subgroups for the 5-year OS (94.4% vs 95.4%, p = 0.667) and DFS (90.1% vs. 91.1%, p = 0.798). By the date of the last follow-up, 8.96% (n = 36) of the patients experienced any recurrence. Univariate analysis revealed that PMRT was not a prognostic factor for either OS (p = 0.667) or DFS (p = 0.798) in T
N
patients. We then did a meta-analysis on the current treatment patterns, in which 2606 PMRT and 4281 non-PMRT T
N
breast cancer patients with mastectomy were included. The meta-analysis showed that PMRT didn't improve the OS of the patients (HR = 0.85, p = 0.11), but patients with PMRT had better DFS than those in the non-PMRT group (HR = 0.62, p < 0.001).
PMRT did not affect the survival of T
N
breast cancer patients who underwent mastectomy, suggesting that radiotherapy may be safely omitted for them.</abstract><cop>Germany</cop><pmid>37256383</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1432-1335 |
| ispartof | Journal of cancer research and clinical oncology, 2023-09, Vol.149 (12), p.9979 |
| issn | 1432-1335 |
| language | eng |
| recordid | cdi_pubmed_primary_37256383 |
| source | SpringerLink Journals - AutoHoldings |
| title | Postmastectomy radiotherapy in patients with T 1-2 N 1 breast cancer: a single center experience and a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A09%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postmastectomy%20radiotherapy%20in%20patients%20with%20T%201-2%20N%201%20breast%20cancer:%20a%20single%20center%20experience%20and%20a%20meta-analysis&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Luo,%20Meng&rft.date=2023-09&rft.volume=149&rft.issue=12&rft.spage=9979&rft.pages=9979-&rft.eissn=1432-1335&rft_id=info:doi/&rft_dat=%3Cpubmed%3E37256383%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37256383&rfr_iscdi=true |